BioVie Inc. Files Q1 2025 10-Q

Ticker: BIVIW · Form: 10-Q · Filed: May 12, 2025 · CIK: 1580149

Biovie Inc. 10-Q Filing Summary
FieldDetail
CompanyBiovie Inc. (BIVIW)
Form Type10-Q
Filed DateMay 12, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceutical

TL;DR

BioVie's Q1 2025 10-Q is in. Check financials.

AI Summary

BioVie Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The company, formerly NanoAntibiotics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector. Key financial details and operational updates for the quarter are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with the latest financial health and operational status of BioVie Inc., crucial for understanding its current market position and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, BioVie Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Players & Entities

  • BIOVIE INC. (company) — Filer
  • NANOANTIBIOTICS, INC. (company) — Former company name
  • 20250331 (date) — Period of report
  • 20250512 (date) — Filing date

FAQ

What is BioVie Inc.'s fiscal year end?

BioVie Inc.'s fiscal year ends on June 30.

What is BioVie Inc.'s Standard Industrial Classification code?

BioVie Inc.'s SIC code is 2834, Pharmaceutical Preparations.

When was BioVie Inc. formerly known as NanoAntibiotics, Inc.?

The company changed its name from NanoAntibiotics, Inc. on June 25, 2013.

What is the filing date of this 10-Q report?

This 10-Q report was filed on May 12, 2025.

What period does this 10-Q filing cover?

This 10-Q filing covers the period ending March 31, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding BIOVIE INC. (BIVIW).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.